Skip to main content

Table 3 Simulated treatment sequences, duration of treatments per patient, and survival in mCRPC

From: Drug costs in the management of metastatic castration-resistant prostate cancer in Canada

Current model       
Treatment sequence AA AAwd Docetaxel Abiraterone OtherTx  
% of patients receiving each line of treatment 100% 88.1% 72.7% 54.2% 29.4%  
  Mean duration per patient (95%CI)* 8.5 (8.4-8.6) 4.3 (4.3-4.4) 7.1 (7.0-7.1) 10 (9.9-10.2) 14.6 (14.3-14.9)  
  Median duration per patient (IQR)* 8 (5–12) 4 (3–6) 7 (7–8) 9 (4–17) 15 (6–24)  
  Mean Survival (95%CI)** 28.1 (27.7-28.4) 22.1 (21.7-22.4) 21.3 (20.9-21.6) 18.8 (18.4-19.1) 15.2 (14.9-15.5)  
  Median Survival (IQR)** 25 (14–40) 19 (7–24) 18 (9–32) 16 (8–28) 16 (7–24)  
Alternate model       
Treatment sequence AA AAwd Abiraterone Docetaxel Cabazitaxel OtherTx
% of patients receiving each line of treatment 100% 88.0% 72.6% 47.4% 35.4% 26.9%
  Mean duration per patient (95%CI)* 8.6 (8.5-8.7) 4.4 (4.3-4.4) 20.2 (19.9- 20.4) 7.0 (7.0-7.1) 5.7 (5.6-5.8) 15.0 (14.7-15.4)
  Median duration per patient (IQR)* 8 (5–12) 4 (3–6) 19 (9–35) 7 (7–8) 5 (4–7) 16 (7–24)
  Mean Survival (95%CI)** 37.3 (36.8-37.8) 32.5 (32.0-32.9) 33.8 (33.4.0-34.3) 20.4 (20.1-20.8) 17.6 (17.3-17.9) 15.7 (15.4-16.0)
  Median Survival (IQR)** 34 (15–56) 30.0 (12–50) 32 (17–48) 18 (9–34) 17 (8–28) 17 (8–24)
  1. *in each treatment-specific state (95% CI) (months); **from entry into the treatment-specific state (IQR: 25 and 75 percentile);
  2. Abbreviations: 95% CI 95% confidence interval, IQR Interquartile range, AA Anti-androgen, AAwd Anti-androgen withdrawal, OtherTx Other treatments.
\